Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher T. Giordano
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Beta
- 0.93
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.46
Financials
Revenue
$0.00-100.0%Net Income
$-17.80MEBITDA
$-18.78MFree Cash Flow
$-14.15MEPS (diluted)
$-0.35Shares Outstanding (diluted)
50.87M+5787073.9%Operating Expenses
$18.78MCash & Debt
$117.98MReturn of Capital
$0.00Revenue by Segment (annual)
$46.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-52.60M | $-1.34 |
| 2024 | $0.00 | $-17.60M | $-1.15 |
| 2023 | $0.00 | $-7.71M | $-31.04 |
| 2022 | $0.00 | $-11.05M | $-600.80 |
| 2021 | $0.00 | $-32.47M | $-2524.80 |
| 2020 | $0.00 | $-9.85M | $-2125.38 |
| 2019 | $0.00 | $-8.39M | $-26.60 |
| 2018 | $0.00 | $-6.81M | $-7359.14 |
| 2017 | $0.00 | $-8.84M | $-10022.32 |
| 2016 | $0.00 | $-43.92M | $-624.82 |
| 2015 | $49.3K | $-14.08M | $-200.61 |
| 2014 | $49.3K | $-14.08M | $-16038.51 |
| 2013 | $288.7K | $-19.54M | $-2282.62 |
| 2012 | $1.23M | $-9.42M | $-172897.85 |
Valuation
TENXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-78.57%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·38d ago·Negative
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
View source ↗ - Newsbusinesswire.com·50d ago·Negative
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsmarketbeat.com·56d ago·Negative
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.
View source ↗ - Newsbenzinga.com·56d ago·Negative
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.35 per share
Typical surprise +46.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$-0.35 vs $-0.38beat
- Tue, May 12$-0.35 vs $-0.40beat
- Tue, Mar 10$-0.38 vs $-1.26beat
- Wed, Nov 12$-0.40 vs $-1.33beat
- Wed, Aug 13$-0.27 vs $-0.50beat
- Wed, May 14$-0.28 vs $-0.48beat
Estimates and results for TENX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TENX officers and directors.
- Bought
- $5.3m
- Sold
- —
30 trades
0 trades
- Doogan Declanbought
- Giordano Christopher Thomasbought
- Giordano Christopher Thomasbought
- Staab Thomas R Iibought
- Adar1 Capital Management, Llcbought
- Adar1 Capital Management, Llcbought
- Adar1 Capital Management, Llcbought
- Adar1 Capital Management, Llcbought
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TENX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.